N-acyl glycine residue is known to interact with renal tubular transport enzymes and thereby promotes renal tubular secretion. Recently, a similar renal property was also observed with dioxotechnetium aminocarboxy chelates. Therefore, a radiopharmaceutical was designed containing both the above groups with the expectation that an efficient 99mTc labelled renal tubular agent could be developed by this process with which evaluation of various renal parameters will be possible. The synthesized compound, though secreted through the renal tubular pathway, did not show the expected efficiency. It was indicated that the renal property of the molecule was entirely due to chelated dioxotechnetium moiety and the expected effect of the acyl glycine residue was not observed in the molecule.